39.60
+2.33%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zenith Drugs
Its shares trade on NSE under the ticker ZENITHDRUG.NS. It has been listed since 27 February 2024. In the fiscal year to 31 March 2025, it reported revenue of ₹1.33bn and net income of ₹71.6m. At that date it held total assets of ₹1.61bn and shareholders' equity of ₹693.8m.
Zenith Drugs Ltd is a IN-based company operating in industry. The company is headquartered in Indore, Madhya Pradesh. The company went IPO on 2024-02-27. Zenith Drugs Ltd is an India-based pharmaceutical manufacturing and trading company. The firm is specialized in manufacturing medicines. The firm offers a wide range of formulations in various forms, such as oral rehydration solution (ORS) powder, liquid oral, ointments, creams, gels and liquid externals, capsules, tablets. Its domestic products include Electrolytes (ORS), Anti Inflammatory - Antiemetic, Cold - Cough, Antihistaminic & Antiasthmatic, Antibacterial - Antifungal, Calamine & Liquid Paraffin, Omeprazole capsules, Loperamide capsules, Pantoprazole and domperidone capsules, Rabeprazole and domperidone capsules, Tricholine Citrate & Sorbitol, among others. Its generic division offers Biozen, and RHON - POULE.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 27 Feb 2024
- Website
- zenithdrugs.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zenith Drugs Ltd specializes in manufacturing medicines with a wide range of formulations including ORS powder and liquid oral forms.
- The company offers domestic products like Electrolytes (ORS) and Anti Inflammatory - Antiemetic for diverse health needs.
- Zenith Drugs Ltd's generic division provides Biozen and RHON - POULE for cost-effective healthcare solutions.
Weaknesses
- Zenith Drugs Ltd is a newly listed company on 27 February 2024 with limited market presence.
- The company operates primarily in the Indian market without international expansion strategies.
- Zenith Drugs Ltd has no mention of R&D investment in its business description.
Opportunities
- The Indian pharmaceutical market offers significant growth potential for Zenith Drugs Ltd's domestic product range.
- Zenith Drugs Ltd can expand its generic division Biozen and RHON - POULE into new segments like OTC medications.
- Increasing demand for affordable medicines in India supports Zenith Drugs Ltd's focus on cost-effective healthcare solutions.
Threats
- The Indian pharmaceutical industry faces intense competition from established players like Sun Pharma and Dr. Reddy's.
- Regulatory changes in India could impact Zenith Drugs Ltd's manufacturing and trading operations.
- Economic downturns in India may reduce consumer spending on non-essential medications.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.